switching glp 1 agonists Science Behind GIP and Glucagon Receptor for Obesity Research | News & Announcements GLP-1 Receptor Agonists as Treatments
Description
J Neurosci
They offer cost-effective treatment options because they can self-amplify and autonomously produce therapeutic agents
Four key questions on the new wave of anti-obesity drugs
12 Additionally, DPP4 was found to be significantly expressed in osteoclasts, and its activity was inhibited by the anti-resorptive drug denosumab, suggesting that DPP4 produced by osteoclasts could play a crucial role in bone remodeling and energy metabolism
